Mobocertinib has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
What are the common side effects of Mobocertinib?
Mobocertinib is a targeted therapy that can inhibit tumor growth and spread by targeting specific cancer cell signaling pathways, thereby prolonging patient survival and improving treatment efficacy. However, there are certain side effects, which are as follows.
Digestive side effects
Mobocertinib may cause digestive side effects such as diarrhea, nausea, vomiting, loss of appetite, and gastrointestinal reactions are usually mild to moderate and can be improved with dietary modifications, medications, or other modalities.
Skin side effects
Mobocertinib may cause skin reactions such as rash, dryness, itching, etc., but in rare cases, it may develop into severe skin inflammation. Patients should maintain good skin care and avoid excessive friction or irritation.
Oral side effects
Mobocertinib may cause inflammation of the oral mucosa, manifesting as oral pain, ulcers, or dry mouth. Maintain good oral hygiene and avoid irritating foods and drinks.
Patients should communicate with their doctor promptly during the use of Mobocertinib and inform them of any changes in discomfort or symptoms. Doctors can assess the severity of side effects and adjust the dose of medication or provide supportive care as needed.
How to use Mobocertinib?
Mobocertinib produced by Takeda in Japan is in capsule dosage form, with the words "MB788" printed on the cap of the drug bottle and the words "40mg" printed on the bottle body in black ink.
How to use medications
Mobocertinib capsules need to be swallowed whole, do not open, chew or dissolve the contents of the capsules. Because the drug is packaged in a specific form and dosage in capsules to ensure that the drug is released at the right time and place to allow it to work in the body.
Dosage of the drug
The recommended dose of Mobocertinib is 160 mg orally once daily. This dosage is determined based on clinical trials and practical experience to achieve the best therapeutic effect. It is generally recommended to take the drug at the same time each day to help maintain a stable concentration of the drug in the body. You can choose to take it before or after meals, and decide whether to accompany the diet or not according to personal habits and the guidance of your doctor.
Medication missed dose recommendations
If you accidentally miss a dose of Mobocertinib and it has been more than 6 hours, it is recommended to skip the dose and take the next dose at the regular time the next day. Do not attempt to catch up on missed doses to avoid overdosing. If you vomit after taking Mobocertinib, do not take another dose and can wait until the next day to continue taking the prescribed dose.
The above dosage and dosing guidelines are for reference only, please always follow the specific instructions of your doctor or pharmacist, who will determine the appropriate dosage and method of use of Mobocertinib according to your individual situation and condition.
During the use of Mobocertinib, it is necessary to have regular clinical examinations and monitoring, such as blood tests, imaging tests, etc., to evaluate the efficacy and safety of the drug. These tests help doctors monitor changes in the condition and adjust treatment plans in a timely manner.
